Categories: News

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022

CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2021 financial results after the Nasdaq Global Market closes on Tuesday, March 1, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2021 financial results and to provide a corporate update.

The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The passcode for the call is 8075225. Please specify to the operator that you would like to join the “Sarepta Fourth Quarter and Full-Year 2021 Earnings Call.” The conference call will be webcast live under the investor relations section of Sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information
We routinely post information that may be important to investors in the ‘For Investors’ section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com

Staff

Recent Posts

Humana Redefines the Member Experience with Agent Assist Built with Google Cloud

Humana introduces Agent Assist to help member advocates deliver faster, more personalized support, enabled by…

2 hours ago

AssureCare Announces Parth Shah’s Promotion to Senior Vice President of Customer Success and Enterprise AI Delivery

CINCINNATI, Feb. 3, 2026 /PRNewswire/ -- AssureCare® LLC, a leading healthcare technology company delivering an…

2 hours ago

Doxim Scales Utility Payments Team to Support Rapid Market Growth

Doxim's Utility Payments Team will drive seamless, omnichannel billing-to-payments solutions for utilities to bridge the…

2 hours ago

Amplifire Recognized by Brandon Hall Group for Breakthrough AI Authoring Technology

BOULDER, Colo., Feb. 3, 2026 /PRNewswire/ -- Amplifire, the leading adaptive learning platform built on patented…

2 hours ago

Cognision Launches Cognision360™: A Unified Platform Transforming Neurobiomarker Acquisition, Processing, and Analysis in CNS Clinical Trials

LOUISVILLE, Ky., Feb. 3, 2026 /PRNewswire/ -- Cognision today unveiled Cognision360™, a groundbreaking web-based platform that consolidates…

2 hours ago